WallStSmart

HCA Healthcare, Inc. (HCA)vsNewGenIvf Group Limited Class A Ordinary Shares (NIVF)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

HCA Healthcare, Inc. generates 1616098% more annual revenue ($76.39B vs $4.73M). NIVF leads profitability with a 209.0% profit margin vs 8.9%. NIVF trades at a lower P/E of 0.0x. HCA earns a higher WallStSmart Score of 63/100 (C+).

HCA

Buy

63

out of 100

Grade: C+

Growth: 5.3Profit: 8.0Value: 5.3Quality: 6.0
Piotroski: 5/9Altman Z: 1.71

NIVF

Buy

58

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 6.7Quality: 9.0
Piotroski: 4/9Altman Z: 4.07
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HCASignificantly Overvalued (-85.7%)

Margin of Safety

-85.7%

Fair Value

$286.26

Current Price

$372.13

$85.87 premium

UndervaluedFair: $286.26Overvalued

Intrinsic value data unavailable for NIVF.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HCA4 strengths · Avg: 9.3/10
Return on EquityProfitability
136.3%10/10

Every $100 of equity generates 136 in profit

Debt/EquityHealth
-7.9110/10

Conservative balance sheet, low leverage

Market CapQuality
$80.58B9/10

Large-cap with strong market position

P/E RatioValuation
12.5x8/10

Attractively priced relative to earnings

NIVF6 strengths · Avg: 9.8/10
P/E RatioValuation
0.0x10/10

Attractively priced relative to earnings

Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Return on EquityProfitability
79.4%10/10

Every $100 of equity generates 79 in profit

Profit MarginProfitability
209.0%10/10

Keeps 209 of every $100 in revenue as profit

Altman Z-ScoreHealth
4.0710/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Areas to Watch

HCA2 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.3%4/10

4.3% revenue growth

Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

NIVF3 concerns · Avg: 2.7/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.77M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
-349.1%1/10

Operating margin of -349.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : HCA

The strongest argument for HCA centers on Return on Equity, Debt/Equity, Market Cap. PEG of 1.12 suggests the stock is reasonably priced for its growth.

Bull Case : NIVF

The strongest argument for NIVF centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 209.0% and operating margin at -349.1%. Revenue growth of 11.9% demonstrates continued momentum.

Bear Case : HCA

The primary concerns for HCA are Revenue Growth, Altman Z-Score.

Bear Case : NIVF

The primary concerns for NIVF are EPS Growth, Market Cap, Operating Margin.

Key Dynamics to Monitor

HCA profiles as a value stock while NIVF is a mature play — different risk/reward profiles.

HCA carries more volatility with a beta of 1.19 — expect wider price swings.

NIVF is growing revenue faster at 11.9% — sustainability is the question.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HCA scores higher overall (63/100 vs 58/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

HCA Healthcare, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

HCA Healthcare is an American for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owns and operates 186 hospitals and approximately 2,000 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 21 states and the United Kingdom.

Visit Website →

NewGenIvf Group Limited Class A Ordinary Shares

HEALTHCARE · MEDICAL CARE FACILITIES · USA

NewGenIvf Group Limited (NIVF) is a prominent player in the reproductive health sector, specializing in innovative fertility solutions and advanced in vitro fertilization (IVF) services. With a commitment to enhancing success rates in assisted reproductive technology, NIVF is well-positioned to capitalize on the growing global demand for fertility treatments, supported by an extensive network of clinics and strategic partnerships. As the fertility services market continues to evolve, NIVF is positioned for considerable growth, dedicated to empowering individuals and couples in their journey to parenthood.

Want to dig deeper into these stocks?